» Articles » PMID: 11500500

New Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2001 Aug 14
PMID 11500500
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Defective binding of apolipoprotein E (apoE) to heparan sulfate proteoglycans (HSPGs) is associated with increased risk of atherosclerosis due to inefficient clearance of lipoprotein remnants by the liver. The interaction of apoE with HSPGs has also been implicated in the pathogenesis of Alzheimer's disease and may play a role in neuronal repair. To identify which residues in the heparin-binding site of apoE and which structural elements of heparan sulfate interact, we used a variety of approaches, including glycosaminoglycan specificity assays, (13)C nuclear magnetic resonance, and heparin affinity chromatography. The formation of the high affinity complex required Arg-142, Lys-143, Arg-145, Lys-146, and Arg-147 from apoE and N- and 6-O-sulfo groups of the glucosamine units from the heparin fragment. As shown by molecular modeling, using a high affinity binding octasaccharide fragment of heparin, these findings are consistent with a binding mode in which five saccharide residues of fully sulfated heparan sulfate lie in a shallow groove of the alpha-helix that contains the HSPG-binding site (helix 4 of the four-helix bundle of the 22-kDa fragment). This groove is lined with residues Arg-136, Ser-139, His-140, Arg-142, Lys-143, Arg-145, Lys-146, and Arg-147. In the model, all of these residues make direct contact with either the 2-O-sulfo groups of the iduronic acid monosaccharides or the N- and 6-O-sulfo groups of the glucosamine sulfate monosaccharides. This model indicates that apoE has an HSPG-binding site highly complementary to heparan sulfate rich in N- and O-sulfo groups such as that found in the liver and the brain.

Citing Articles

β-Amyloid Induces Microglial Expression of GPC4 and APOE Leading to Increased Neuronal Tau Pathology and Toxicity.

Holmes B, Weigel T, Chung J, Kaufman S, Apresa B, Byrnes J bioRxiv. 2025; .

PMID: 40060520 PMC: 11888210. DOI: 10.1101/2025.02.20.637701.


APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology.

Tran K, Kwang N, Butler C, Gomez-Arboledas A, Kawauchi S, Mar C Mol Neurodegener. 2025; 20(1):9.

PMID: 39844286 PMC: 11752804. DOI: 10.1186/s13024-024-00793-x.


The role of GZMA as a target of cysteine and biomarker in Alzheimer's disease, pelvic organ prolapse, and tumor progression.

Li Y, Wang Z, Kong M, Yong Y, Yang X, Liu C Front Pharmacol. 2024; 15:1447605.

PMID: 39228516 PMC: 11368878. DOI: 10.3389/fphar.2024.1447605.


Protective Effects of High-Density Lipoprotein on Cancer Risk: Focus on Multiple Myeloma.

Allegra A, Murdaca G, Mirabile G, Gangemi S Biomedicines. 2024; 12(3).

PMID: 38540127 PMC: 10967848. DOI: 10.3390/biomedicines12030514.


The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation.

Nelson M, Liu P, Agrawal A, Yip O, Blumenfeld J, Traglia M Nat Neurosci. 2023; 26(12):2104-2121.

PMID: 37957317 PMC: 10689245. DOI: 10.1038/s41593-023-01480-8.